ReviewVirology2012
Cellular transformation by human papillomaviruses: lessons learned by comparing high- and low-risk viruses.
Review in Virology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
82 citing papers in PubMed, 169 citations in OpenAlex.
- Towards Global HPV Eradication: Single-Dose HPV Vaccination vs. Pseudoscience.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026Article
- Human papillomavirus E7 inhibits immune responses in keratinocytes by activating HTRA1‑mediated mitophagy.International journal of molecular medicine · 2026Article
- Systems Analysis of miRNA-Mediated Host Regulatory Response in HPV-Associated Cervical Malignancy.Computational and structural biotechnology journal · 2026Article
- Exploitation of Biocomputational Approaches for siRNA-Mediated Gene Silencing of HPV: A Novel Therapeutic Strategy for Cervical Cancer.Cancer reports (Hoboken, N.J.) · 2025Article
- Molecular Insights into HPV-Driven Head and Neck Cancers: From Viral Oncoproteins to Precision Therapeutics.Viruses · 2025Review
- HPV16 E6 and E7 expressing cancer cells suppress the antitumor immune response by upregulating KLF2-mediated IL-23 expression in macrophages.Journal for immunotherapy of cancer · 2025Article
- NF-κB Activation Is Essential for Cervical Cell Proliferation and Malignant Transformation.International journal of molecular sciences · 2025Article
- Augmented immunogenicity of the HPV16 DNA vaccine via dual adjuvant approach: integration of CpG ODN into plasmid backbone and co-administration with IL-28B gene adjuvant.Virology journal · 2025Article
- Review
- The Natural History of Cervical Cancer and the Case for MicroRNAs: Is Human Papillomavirus Infection the Whole Story?International journal of molecular sciences · 2024Review
- The role of HR-HPV integration in the progression of premalignant lesions into different cancer types.Heliyon · 2024Review
- Preclinical Immunogenicity and Efficacy Studies for Therapeutic Vaccines for Human Papillomavirus-Type-16-Associated Cancer.Vaccines · 2024Article
- HPV16 Impacts NHERF2 Expression in Oropharyngeal Cancers.Pathogens (Basel, Switzerland) · 2023Article
- Multiomics analysis of metabolic heterogeneity in cervical cancer cell lines with or without HPV.Frontiers in oncology · 2023Article
- Single-Step Synthesis of Ag Hexagonal Nanoplate-Decorated Reduced Graphene Oxide and Its Cytotoxicity Studies.Oxidative medicine and cellular longevity · 2023Article
- Pioneer factors in viral infection.Frontiers in immunology · 2023Review
- Does Human Papillomavirus Infection Influence the Frequency and Severity of Nutritional Disorders in Head and Neck Cancer?Nutrients · 2022Review
- The Drivers, Mechanisms, and Consequences of Genome Instability in HPV-Driven Cancers.Cancers · 2022Review
- Oral Papillomatosis: Its Relation with Human Papilloma Virus Infection and Local Immunity-An Update.Medicina (Kaunas, Lithuania) · 2022Review
- Human papillomaviruses: diversity, infection and host interactions.Nature reviews. Microbiology · 2022Review
22 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The oncogenic potential of papillomaviruses (PVs) has been appreciated since the 1930s yet the mechanisms of virally-mediated cellular transformation are still being revealed. Reasons for this include: a) the oncoproteins are multifunctional, b) there is an ever-growing list of cellular interacting proteins, c) more than one cellular protein may bind to a given region of the oncoprotein, and d) there is only limited information on the proteins encoded by the corresponding non-oncogenic PVs. The perspective of this review will be to contrast the activities of the viral E6 and E7 proteins encoded by the oncogenic human PVs (termed high-risk HPVs) to those encoded by their non-oncogenic counterparts (termed low-risk HPVs) in an attempt to sort out viral life cycle-related functions from oncogenic functions. The review will emphasize lessons learned from the cell culture studies of the HPVs causing mucosal/genital tract cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.